Movement Disorders

A phase 2 trial showed the effectiveness of a home-based, full-body movement exergaming program for Parkinson disease compared with control.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Neurology News Network for the week ending January 13, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 12, 2024.

A case series highlighted the significance of using multimodal imaging, such as spectral domain OCT, in detecting ocular manifestations in SCA type 7.

Cala Health's transcutaneous afferent patterned stimulation demonstrated significant efficacy in patients with essential tremor, as evidenced by positive outcomes in multiple clinical studies.

A recently published study showed patients with Friedreich Ataxia treated with medications that enhanced mitochondrial function demonstrated improvement in clinical outcomes and left ventricular mass index.

Approved in Europe in late 2022, the 24-hour continuous subcutaneous infusion acts as a novel and effective treatment option for patients with advanced levodopa-responsive Parkinson disease.

Additional data, including secondary end points and other efficacy assessments, are expected to be presented at an upcoming scientific meeting.

A recent study revealed that tandospirone citrate exhibits more positive effects in alleviating depression/anxiety and cerebellar ataxia symptoms in patients with multiple system atrophy-cerebellar subtype compared with escitalopram oxalate.

Catch up on any of the neurology news headlines you may have missed over the course of January 2024, compiled all into one place by the NeurologyLive® team.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 5, 2024.

The expert neurologists discuss non-motor symptoms of Parkinson’s disease: types, their impact on patient’s quality of life, and current and emerging treatment options for non-motor symptoms.

Catch up on any of the neurology news headlines you may have missed over the course of December 2023, compiled all into one place by the NeurologyLive® team.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2024 that neurology health care professionals should keep their eyes on.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2023.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 29, 2023.

In 2023, these episodes of the Mind Moments® podcast got the most attention from listeners, with this list brought to you as part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in movement disorders in 2023.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 22, 2023.

Researchers have successfully grown norepinephrine neurons from stem cells, which are critical for regulating various bodily functions, offering new insights into neurodegenerative diseases such as Alzheimer and Parkinson.

The research aimed to assess FMD prevalence and clinical manifestations in both elderly and younger onset individuals, revealing insights into symptom variations across different age groups.

According to a recent study, investigators found no reports of moderate or severe adverse events with a high dose of nicotinamide riboside therapy in patients with Parkinson disease.

In newly released data, AMT-130 showed a manageable safety profile at both low and high doses in patients with Huntington disease, supporting the gene therapy's continued development.

A recent systematic practice review outlined pragmatic recommendations to enhance palliative care for patients with Parkinson disease and their caregivers, emphasizing integration, coordination, and personalized care plans.

In a recent case study of a 32-year-old man diagnosed with Friedreich ataxia, parental sample testing identified a novel intragenic deletion involving the 5'UTR upstream region and exons 1 and 2 of the FXN gene.